AdvisorShares Investments LLC Has $252,000 Holdings in GH Research PLC (NASDAQ:GHRS)

AdvisorShares Investments LLC lifted its position in shares of GH Research PLC (NASDAQ:GHRS) by 15.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 36,011 shares of the company’s stock after acquiring an additional 4,806 shares during the quarter. AdvisorShares Investments LLC’s holdings in GH Research were worth $252,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Northern Trust Corp boosted its stake in shares of GH Research by 26.8% during the fourth quarter. Northern Trust Corp now owns 40,834 shares of the company’s stock valued at $286,000 after purchasing an additional 8,641 shares in the last quarter. Geode Capital Management LLC boosted its position in GH Research by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 72,513 shares of the company’s stock worth $508,000 after buying an additional 3,092 shares during the period. Diadema Partners LP bought a new stake in GH Research during the 4th quarter worth approximately $711,000. Finally, Lynx1 Capital Management LP increased its position in GH Research by 15.8% in the 4th quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock valued at $34,013,000 after acquiring an additional 663,100 shares during the period. Institutional investors own 56.90% of the company’s stock.

GH Research Stock Performance

GH Research stock opened at $9.00 on Wednesday. The stock has a market capitalization of $468.25 million, a price-to-earnings ratio of -11.39 and a beta of 0.84. GH Research PLC has a 52-week low of $6.00 and a 52-week high of $20.50. The stock’s 50 day moving average price is $10.35 and its two-hundred day moving average price is $9.70.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. On average, equities research analysts forecast that GH Research PLC will post -0.8 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on GHRS shares. Cantor Fitzgerald began coverage on shares of GH Research in a report on Thursday, February 13th. They set an “overweight” rating and a $14.00 price target on the stock. Royal Bank of Canada started coverage on GH Research in a research report on Friday, March 7th. They issued an “outperform” rating and a $31.00 price target on the stock. Guggenheim began coverage on GH Research in a research report on Thursday, March 13th. They set a “buy” rating and a $32.00 price objective for the company. Stifel Nicolaus upped their target price on GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, February 27th. Finally, HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of GH Research in a report on Monday, January 27th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, GH Research has an average rating of “Buy” and a consensus target price of $30.86.

GH Research Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).